Peter Winter, consultant to the biotechnology industry brings us financings and business developments in the global diagnostics business in his new column “This Week In Diagnostics“. Peter has over 30 years experience as a scientist, science journalist, and publisher.
Browsing: Diagnostics Techreport
Peter Winter, consultant to the biotechnology industry brings us financings and business developments in the global diagnostics business. Peter has over 30 years experience as a scientist, science journalist, and publisher.
Biocept, Inc., a privately-held CLIA-certified laboratory testing company, and Clarient, Inc. (a GE Healthcare Company) say that they will be collaborating on the commercialization of a proprietary blood test for circulating tumor cells…
Ikonisys is a medical devices company that has developed a combinatorial technological platform using molecular biology and imaging methodology for the detection of rare cells, including cancer cells, and for the prenatal diagnosis of rare genetic disorders. The company’s proprietary cell-optics platform is an automated cell based diagnostic system that uses a highly sophisticated digital microscopy unit that can detect disease-specific cellular components and fluorescently labeled disease markers, enabling the detection and analysis of disease progression. The company has received FDA clearance for its fluorescent-based diagnostics of breast cancer, bladder cancer, and amniotic fluid prenatal genetic disorder screen. Fluorescent light-based…
Technology that enables the fast and sensitive detection of biological and disease specific markers in live tissue is a major need in the diagnostic field. VisEn Medical has developed a breakthrough proprietary platform that utilizes very specific fluorescent light based technology to enable non-invasive, real time visualization and quantification of normal and disease specific markers both at the time of diagnosing and during ongoing medical treatment. The company’s technology utilizes near infrared wavelength light that does not significantly react with normal tissue, in conjunction with proprietary FMT fluorescent imaging technology and fluorescent tags, to label and image biological markers of…
Antibody based diagnostics and therapeutics represent a major medical advance as they respectively identify diseases with high specificity and preclude systemic side effects by recognizing diseased tissue only, yet an important drawback that current technology suffers from is the inability to detect intracellular markers that represent a high majority of disease identifiers. To address this concern, Receptor Logic has developed a breakthrough technological platform to actualize antibodies that detect soluble and tissue-present disease markers, as well as previously undetectable intracellular disease markers, thereby enabling significantly improved diagnostic sensitivity and therapeutic treatment. Receptor Logic is a biopharmaceutical company that has actualized…
The streamlining of advanced molecular diagnostics, particularly in genetics, is essential for expanding the use of the most cutting-edge technology throughout the healthcare industry. PlexPress s a biopharmaceutical company that has developed a straightforward technology that allows high thorough-put, large scale genetic analysis that not only detects gene expression, but also details the level of expression seen in disease states, as opposed to normal health conditions. The company’s technological platform functions by isolating genetic material from cells and exposing them to fluorescent probes that bind the gene-targets of interest. Next, the identifying fluorescent signals are detected and quantified using an…
Identification and detection of new biomarkers that identify the beginning stages of diseases is critical for achieving successful medical treatment. EDP Biotech Corporation is a medical device company that is developing a sophisticated technological platform for detecting early stage colon cancer from minimal patient blood samples, enabling early diagnosis, in a timely and cost effective manner. This technology is poised to transform colon cancer patient screening to a simple blood test that saves both time and money, as well as vastly improves patient compliance and prognosis, since current methodologies are more invasive and have a significantly lower detection rate.